RxDoctor Payments Data

Michael Cheng, MD

Gastroenterology · Covington, GANPI 1942303276

Payments from drug & device makers

$9,916in general payments, 2019–2025

Across 236 payments — averaging $42.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$6K
  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$528
  • Boston Scientific$348
  • Johnson & Johnson$303
  • Takeda Pharmaceuticals U.S.A., Inc.$287
  • plus $1K from 17 others

What the payments were for

  • Speaking & faculty fees$4,30043%
  • Travel & lodging$7437%
  • Food & beverage$4,55346%
  • Education$3203%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,916 in reported general payments places this provider in the 75th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$118,387
Medicare patients
351
Services billed
994

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase33$116,821
LinzessLinaclotide132$98,882
XifaxanRifaximin26$73,938
Mesalamine17$9,852
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates58$3,748
Pantoprazole Sodium404$2,326
Famotidine281$2,102
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl129$1,904
Peg3350-Sod Sul-Nacl-Kcl-Asb-CPeg3350/Sod Sul/Nacl/Kcl/Asb/C22$1,672
Lubiprostone11$1,030
Sucralfate48$891
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl51$746
Ondansetron OdtOndansetron20$439
Omeprazole65$418
Dicyclomine Hcl24$326

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,279$215,703165 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$528$73,93826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Covington

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →